PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

4,093

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
COVID19
Interventions
DRUG

Icosapent ethyl (IPE)

"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"

DRUG

Placebo

Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)

Trial Locations (1)

2000

Instituto de Investigaciones Clínicas - Rosario, Rosario

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amarin Pharma Inc.

INDUSTRY

lead

Estudios Clínicos Latino América

OTHER